ACO Assignment Improvement Act of 2025

1) What happened: Rep. Adrian Smith (R-NE) introduced HR4773 on July 25, 2025, which was referred to the House Ways & Means and Energy & Commerce Committees. It is early-stage — referred to committee with no hearings yet. A Senate companion bill (S3350) was introduced and referred to Finance. The bill amends Medicare's Shared Savings Program to attribute beneficiaries to ACOs based on primary care visits to PAs, NPs, and CNSs, not just physicians, effective performance years starting January 2027. 2) The money trail: This is a statute change — NOT an appropriation. No direct federal funding is authorized or allocated. The financial impact comes from redistributing Medicare shared savings payments: more beneficiaries assigned to ACOs means larger shared savings pools for participating ACO entities, which are typically operated by or affiliated with large managed care organizations. CMS would incur implementation costs for updating assignment algorithms, but the Congressional Budget Office would score the bill as reducing Medicare spending if ACOs generate net savings, or increasing spending if bonus payments exceed savings — not yet scored. 3) Structural winners: UnitedHealth (Optum ACOs + UHC Medicare Advantage), Humana (value-based MA plans), and CVS (Aetna + Oak Street Health) are the primary beneficiaries. Each operates large ACO footprints or Medicare Advantage plans that coordinate care through ACO relationships. No direct losers — traditional fee-for-service providers are unaffected because assignment expansion only adds to ACO attribution, not removing existing beneficiaries. 4) Real market data: Over the past 30 days, has surged +41.62% to $370.74, $HUM +46.46% to $243.12, and $CVS +19.62% to $83.90 — all significantly outperforming the broader market. The 7-day changes (+4.56%, +13.11%, +6.39% respectively) show accelerating momentum. While much of this is likely driven by broader Medicare Advantage sentiment and earnings expectations, the introduction and committee referral of HR4773 provides a modest additional tailwind. Note that $HUM is trading closer to its 52-week mid-range, while and $CVS are near their highs, suggesting different risk profiles. 5) Timeline: The bill faces a long legislative path — committee hearings, markup, House floor vote, Senate passage through Finance Committee, conference committee if amendments differ, and Presidential signature. With the 119th Congress in its second year (2026), a narrow window exists for passage. The bill's early stage and lack of hearings suggest FY2027 passage is unlikely unless added as an amendment to a must-pass Medicare package. The January 2027 effective date gives CMS ~6-9 months post-enactment to implement rulemaking if passed in late 2026. Probability of passage in the 119th Congress: low (~20-30%).